Inform edc4/9/2023 ![]() ![]() Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (Empirica Signal™) and Signal Management, adverse event reporting (Empirica Trace™), applied data standards (WebSDM™), Web-integrated interactive response technologies (Clarix™), and clinical data analysis and reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban LIMS). About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. ![]() “We’re pleased to be supporting their efforts to constantly advance the treatment options for a disease that affects quality of life for millions of people worldwide.” Novo Nordisk is a healthcare company and a world leader in diabetes care. “InForm’s ability to easily integrate with other in-house systems and the product’s scalability have been crucial to the implementation, enabling our team to streamline data collection for complex studies spanning multiple geographies.” “Novo Nordisk is a global leader in diabetes care,” said Bob Weiler, chairman and CEO of Phase Forward. “We’ve had a very successful collaboration with Phase Forward over the last three years, and look forward to expanding the relationship,” said Henrik Lynge, Head of Clinical System Management in Novo Nordisk. Novo Nordisk is currently using InForm to support trials in more than 30 countries. ![]() Since signing an application service provider (ASP) arrangement in mid-2006, Novo Nordisk has successfully implemented and integrated global InForm studies with internal systems. Novo Nordisk plans to use Phase Forward’s InForm™ electronic data capture (EDC) product as the default data capture system across all clinical trial phases, from Phases I through IV. ![]() WALTHAM, Mass.-(BUSINESS WIRE )-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year, multi-million dollar enterprise license and services agreement with Novo Nordisk, expanding the existing relationship between the two companies. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |